当前位置: X-MOL 学术Gastroenterology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms.
Gastroenterology ( IF 29.4 ) Pub Date : 2019-12-19 , DOI: 10.1053/j.gastro.2019.12.014
Sean D Delshad 1 , Christopher V Almario 2 , William D Chey 3 , Brennan M R Spiegel 4
Affiliation  

BACKGROUND & AIMS There are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United States. We performed a population-based study to determine the prevalence of GERD symptoms and persistent GERD symptoms despite use of proton pump inhibitors (PPIs). METHODS We conducted the National Gastrointestinal Survey in 2015 using MyGiHealth, an app that guides participants through National Institutes of Health gastrointestinal PROMIS surveys. Primary outcomes were prevalence of GERD symptoms in the past and persistence of GERD symptoms (heartburn or regurgitation 2 or more days in past week) among participants taking PPIs. Population weights were applied to the data and multivariable regression was used to adjust for confounding. RESULTS Among 71,812 participants, 32,878 (44.1%) reported having had GERD symptoms in the past and 23,039 (30.9%) reported having GERD symptoms in the last week. We also found that 35.1% of those who had experienced GERD symptoms were currently on therapy (55.2% on PPIs, 24.3% on histamine-2 receptor blockers, and 24.4% on antacids). Among 3,229 participants taking daily PPIs, 54.1% had persistent GERD symptoms. Younger individuals, women, Latinos, and participants with irritable bowel syndrome or Crohn's disease were more likely to have continued symptoms, even when taking PPIs. CONCLUSIONS Using a population-based survey, we found GERD symptoms to be common: 2 of 5 participants have had GERD symptoms in the past and 1 of 3 had symptoms in the last week. We also found that half of PPI users have persistent symptoms. Given the significant effect of GERD on quality of life, further research and development of new therapies are needed for patients with PPI-refractory GERD symptoms.

中文翻译:

胃食管反流病和质子泵抑制剂难治性症状的患病率。

背景与目的在美国,关于胃食管反流病(GERD)患病率的数据很少。我们进行了一项基于人群的研究,以确定尽​​管使用了质子泵抑制剂(PPI),但GERD症状和持续性GERD症状的发生率。方法我们于2015年使用MyGiHealth进行了国家胃肠道调查,该应用程序可指导参与者通过美国国立卫生研究院胃肠道PROMIS调查。主要结局是接受PPI的参与者过去GERD症状的患病率和GERD症状的持续性(过去一周内2天或更长时间的胃灼热或反流)。将人口权重应用于数据,并使用多变量回归来调整混杂因素。结果71,812名参与者中,32,878名(44。1%的人表示过去有GERD症状,而23,039(30.9%)的人表示在过去一周有GERD症状。我们还发现,目前有35.1%的患有GERD症状的患者正在接受治疗(PPIs为55.2%,组胺2受体阻滞剂为24.3%,抗酸剂为24.4%)。在每天服用PPI的3,229名参与者中,有54.1%的人患有持续性GERD症状。即使是服用PPI,年轻的个体,女性,拉丁裔和肠易激综合症或克罗恩氏病参与者也更有可能持续出现症状。结论使用基于人群的调查,我们发现GERD症状很常见:过去5名参与者中有2名曾出现GERD症状,而在最后一周中有3名参与者中有1名出现了GERD症状。我们还发现一半的PPI用户具有持续的症状。鉴于GERD对生活质量的重大影响,
更新日期:2020-04-21
down
wechat
bug